Home > Boards > US Listed > Biotechs >

Akari Therapeutics (AKTX)

AKTX RSS Feed
Add AKTX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/9/2020 1:39:08 PM - Followers: 14 - Board type: Free - Posts Today: 0




https://www.akaritx.com/

Akari is focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, and leukotriene system,
for the treatment of rare and orphan diseases with unmet need. We believe that blocking early mediators of inflammation
will prevent initiation and continual amplification of the processes that cause certain diseases.

Nomacopan is a recombinant small protein (16,740 Da) that acts on complement component-C5,
preventing release of C5a and formation of C5b–9 (also known as the membrane attack complex, or MAC),
and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response.

Nomacopan is currently being clinically evaluated in four indications:

  • bullous pemphigoid (BP), , a severe blistering skin disease
    atopic keratoconjunctivitis (AKC), a sight threatening surface of the eye condition
    thrombotic microangiopathys (TMA) including including atypical hemolytic uremic syndrome (aHUS) and hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT TMA)
    paroxysmal nocturnal hemoglobinuria (PNH).

Akari believes that the dual action of nomacopan on both C5 and LTB4 may be beneficial in AKC, BP, and aHUS. Akari is also developing other tick derived proteins, including longer acting versions.

Nomacopan is a highly soluble and stable biological molecule, and independently binds to both C5 and LTB4.  This novel dual binding enables targeting of two distinct and separate disease categories based on their underlying etiology.

Four Primary/Lead Indications in Phase II/III Plus Pipeline of Earlier-Stage Targets



https://www.akaritx.com/bullous-pemphigoid-phase-iia/
https://www.akaritx.com/akc-phase-i-ii/
https://www.akaritx.com/long-term-safety/
https://www.akaritx.com/phn-phase-ii-iii/
phase 2 &3
https://www.akaritx.com/eculizumab-resistant-phase-ii/
https://www.akaritx.com/#
https://www.akaritx.com/mode-of-action/
[/chart]www.akaritx.com/wp-content/uploads/2018/09/Screen-Shot-2018-09-29-at-9.16.55-PM.png[/chart]
https://www.akaritx.com/c5-complement-system/
https://www.akaritx.com/ltb4-leukotrine-system/
https://www.akaritx.com/nomacopan/
https://www.akaritx.com/coversin-la-weekly-formulation/
https://www.akaritx.com/coversin-based-molecules/
 







RECENT PRESS RELEASES

Akari Therapeutics Announces Appointment of Chief Financial Officer

July 1, 2020

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC

July 1, 2020

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2020

June 1, 2020

Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients

May 1, 2020

Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

March 31, 2020






https://finance.yahoo.com/news/akari-therapeutics-reports-first-quarter-110010702.html

Patients with COVID-19 pneumonia

  • The Company believes nomacopan’s dual inhibition of both the complement (C5) and leukotriene (LTB4) pathways makes
    the drug potentially well suited for the treatment of patients with COVID-19 pneumonia and related COVID disease.
    Leukotriene inhibition is a validated pathway for the treatment of severe lung inflammation and LTB4 is a potent granulocyte and
    leukocyte attractant which in turn are key drivers of the damaging cytokine storm that underpins acute respiratory distress syndrome (ARDS).
    Likewise, there is growing evidence of the role of the complement pathway in the microthrombi and organ damage associated with COVID-19 pneumonia.
     
    In pre-clinical lung inflammation models including a study of viral induced lung inflammation, nomacopan (formerly known as Coversin)
    showed significant reductions in key lung inflammatory markers such as neutrophils and lung vascular leakage (Garcia et al., 2013; Roversi et al., 2013).
    Likewise in sepsis models (Huber-Lang et al., 2014) nomacopan has shown significant downregulation of a wide range of pro-inflammatory cytokines
    and chemokines including TNF, IL-6, GM-CSF, IL1alpha, IL1beta, IL17, MCP1 (CCL2), MIP1alpha (CCL3),
    MIP1beta (CCL4) which have all been shown to be elevated in patients with COVID-19 disease.
     
    Akari is actively pursuing several clinical study opportunities in patients with COVID-19 pneumonia in the UK and U.S.
    The Company intends to provide additional detail when these programs are finalized and approved.

https://finviz.com/quote.ashx?t=aktx&ty=c&ta=1&p=d




$AKTX FIVE YR.



https://www.otcmarkets.com/stock/AKTX/disclosure

https://www.otcmarkets.com/stock/AKTX/news

https://www.otcmarkets.com/stock/AKTX/security

https://www.otcmarkets.com/stock/AKTX/profile

https://www.otcmarkets.com/stock/AKTX/quote

https://www.otcmarkets.com/stock/AKTX/overview





 *DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.
AKTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AKTX News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 12/03/2020 04:38:20 PM
AKTX News: Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of... 12/03/2020 10:00:00 AM
AKTX News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 11/16/2020 09:41:00 AM
AKTX News: Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology ... 10/27/2020 09:00:10 AM
AKTX News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 10/06/2020 09:29:06 AM
News News Alert: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 12/03/2020 04:38:20 PM
PostSubject
#544   $AKTX added. MotionOffense78 11/09/20 01:39:08 PM
#543   Lmao. Clueless Rogerthat1 09/05/20 03:49:12 PM
#542   Completely doomed company. Nobody touching it! More vol candeloro 08/31/20 02:27:40 PM
#541   Funny to read the messages from 2 years candeloro 08/27/20 04:05:44 PM
#540   yeah, pretty awful. candeloro 08/27/20 03:55:05 PM
#539   Akari Therapeutics P (AKTX) mick 08/27/20 03:50:52 PM
#538   mick, old pump and dumper. Now 10% lower. candeloro 08/27/20 03:46:38 PM
#537   $AKTX Akari Therapeutics P (AKTX) mick 08/08/20 05:45:33 PM
#536   $AKTX BIG TIME MOVE mick 08/08/20 05:45:17 PM
#535   Added a bunch Friday $AKTX. Have bigly position Rogerthat1 08/08/20 05:24:12 PM
#534   $AKTX Akari Therapeutics PLC (NASDAQ: AKTX): interim update mick 08/05/20 10:39:45 AM
#533   $AKTX going to be huge runner my friend !!!!! mick 07/29/20 09:40:55 PM
#532   $AKTX i am looking fer $8 plus !!!!! mick 07/29/20 09:38:27 PM
#531   $AKTX why not this wk ????? biotech are mick 07/29/20 09:36:54 PM
#530   $AKTX Akari Therapeutics P (AKTX) mick 07/29/20 09:33:53 PM
#529   $AKTX I AGREE WITH PPS , EXCELLENT mick 07/29/20 09:33:37 PM
#528   Agreed. And I'm watching $AKTX for signs to Ablivious 07/29/20 09:55:10 AM
#527   Excellent to see some new posters here. Give BrazenBull 07/29/20 01:09:01 AM
#526   $AKTX here you have Akari’s medical director as Rogerthat1 07/28/20 12:37:10 AM
#525   I was buying $capr at 90¢ and been Rogerthat1 07/27/20 10:01:12 PM
#524   $AKTX YOU ARE WELCOME. AKTX Bid: 2.08 Ask: mick 07/27/20 05:05:00 PM
#523   Thanks for the post Mick. We are gold MotionOffense78 07/27/20 04:55:30 PM
#522   $AKTX Akari Therapeutics (AKTX) $5 target !!!!! mick 07/27/20 12:51:53 PM
#521   $AKTX reading your theory mick 07/25/20 08:34:48 PM
#520   $AKTX READING YOUR DD, outstanding stuff !!!!! mick 07/25/20 08:33:04 PM
#519   $AKTX ih.advfn.com/p.php?pid=staticchart&s=AKTX&p=0&t=17&width=288&height mick 07/25/20 08:31:25 PM
#518   $AKTX i didn't look @ a.h. finished up !!!!! mick 07/25/20 08:30:45 PM
#517   $AKTX, i will try fer more shares !!!!! mick 07/25/20 08:29:25 PM
#516   She ready to go for a run imo Rogerthat1 07/25/20 08:24:52 PM
#515   $AKTX THANX FOR UPDATING. how ya like 5yr. mick 07/25/20 08:20:58 PM
#514   $AKTX GOOD REPORE' mick 07/25/20 08:09:32 PM
#513   Last year had the same pattern. Did a Rogerthat1 07/25/20 08:02:53 PM
#512   $AKTX FIVE YR. mick 07/25/20 07:59:34 PM
#511   $AKTX, I THINK $7 TO $10 PPS MY FRIEND mick 07/25/20 07:57:05 PM
#510   I’ve posted a lot of $AKTX DD on Rogerthat1 07/25/20 06:47:08 PM
#509   $AKTX Akari Therapeutics P (AKTX) mick 07/25/20 02:18:23 PM
#508   $AKTX “We remain focused on our mission of mick 07/24/20 11:28:50 AM
#507   $AKTX ]fast track approval Open pivotal study in mick 07/24/20 11:25:58 AM
#506   $AKTX 1.9700 -0.0300 -1.50% USD 11:20AM EDT 55.152k mick 07/24/20 11:23:35 AM
#505   $AKTX DID YA SEE DIS TRADE ????? ANYONE mick 07/21/20 04:18:37 PM
#504   $AKTX The latest on the coronavirus pandemic mick 07/21/20 02:15:33 PM
#503   $AKTX STRONG BUY !!!!! https://potstocknews.com/stock-quote/AKTX/analyst/ mick 07/21/20 01:45:33 PM
#502   $AKTX Price To Book 37.96 Price to Tangible mick 07/21/20 01:35:06 PM
#501   $AKTX [-chart]www.stockscores.com/chart.asp?TickerSymbol=AKTX&TimeRange=180&Inte mick 07/21/20 12:56:35 PM
#500   $AKTX INDEED , i updated ibox mick 07/21/20 12:15:04 PM
#499   $AKTX a steal at the current pps. Lots MotionOffense78 07/21/20 12:04:08 PM
#498   $AKTX NEW YORK and LONDON, May 29, 2020 mick 07/21/20 11:41:11 AM
#497   $AKTX ]Open pivotal study in pediatric hematopoietic stem mick 07/21/20 11:06:44 AM
#496   $AKTX COULD GO BONKERS !!!!! mick 07/21/20 11:06:08 AM
#495   $AKTX $30MIL AH LOT DOE RE ME, RE;AKTX mick 07/21/20 10:04:21 AM
PostSubject
Consent Preferences